A network-based method for brain disease gene prediction by integrating brain connectome and molecular network.

Brain disease gene identification is critical for revealing the biological mechanism and developing drugs for brain diseases. To enhance the identification of brain disease genes, similarity-based computational methods, especially network-based methods, have been adopted for narrowing down the searching space. However, these network-based methods only use molecular networks, ignoring brain connectome data, which have been widely used in many brain-related studies. In our study, we propose a novel framework, named brainMI, for integrating brain connectome data and molecular-based gene association networks to predict brain disease genes. For the consistent representation of molecular-based network data and brain connectome data, brainMI first constructs a novel gene network, called brain functional connectivity (BFC)-based gene network, based on resting-state functional magnetic resonance imaging data and brain region-specific gene expression data. Then, a multiple network integration method is proposed to learn low-dimensional features of genes by integrating the BFC-based gene network and existing protein-protein interaction networks. Finally, these features are utilized to predict brain disease genes based on a support vector machine-based model. We evaluate brainMI on four brain diseases, including Alzheimer's disease, Parkinson's disease, major depressive disorder and autism. brainMI achieves of 0.761, 0.729, 0.728 and 0.744 using the BFC-based gene network alone and enhances the molecular network-based performance by 6.3% on average. In addition, the results show that brainMI achieves higher performance in predicting brain disease genes compared to the existing three state-of-the-art methods.

An end-to-end heterogeneous graph representation learning-based framework for drug-target interaction prediction.

Accurately identifying potential drug-target interactions (DTIs) is a key step in drug discovery. Although many related experimental studies have been carried out for identifying DTIs in the past few decades, the biological experiment-based DTI identification is still timeconsuming and expensive. Therefore, it is of great significance to develop effective computational methods for identifying DTIs. In this paper, we develop a novel 'end-to-end' learning-based framework based on heterogeneous 'graph' convolutional networks for 'DTI' prediction called end-to-end graph (EEG)-DTI. Given a heterogeneous network containing multiple types of biological entities (i.e. drug, protein, disease, side-effect), EEG-DTI learns the low-dimensional feature representation of drugs and targets using a graph convolutional networks-based model and predicts DTIs based on the learned features. During the training process, EEG-DTI learns the feature representation of nodes in an end-to-end mode. The evaluation test shows that EEG-DTI performs better than existing state-of-art methods. The data and source code are available at: https://github.com/MedicineBiology-AI/EEG-DTI.